Literature DB >> 1468987

Enhancement by ubenimex (bestatin) of host resistance to Candida albicans infection.

K Aoyagi1, N Itoh, F Abe, S Abe, K Uchida, M Ishizuka, T Takeuchi, H Yamaguchi.   

Abstract

Ubenimex is a low molecular weight microbial metabolite which has been demonstrated to have antitumor and immunomodulatory activities. In this study, the protective effect of ubenimex on Candida albicans infection was investigated in normal and immunosuppressed mice. In normal mice, treatment with ubenimex at 0.5, 5 and 25 mg/kg for 5 days prior to infection prolonged survival time in a dose-dependent manner. In immunosuppressed mice treated with a single dose of cyclophosphamide 4 days prior to infection, ubenimex treatment at 5 mg/kg for 5 days significantly increased the number of survivors. Ubenimex-treated mice had a significant increase in number of peritoneal exudate cells with neutrophils as well as enhanced functions, including phagocytosis and active oxygen production. These results suggest the potential usefulness of ubenimex as a prophylactic agent for the management of patients with opportunistic fungal infections.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1468987     DOI: 10.7164/antibiotics.45.1778

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  3 in total

1.  Therapeutic efficacy of human macrophage colony-stimulating factor, used alone and in combination with antifungal agents, in mice with systemic Candida albicans infection.

Authors:  T Kuhara; K Uchida; H Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

Review 2.  Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects.

Authors:  Brigitte Bauvois; Daniel Dauzonne
Journal:  Med Res Rev       Date:  2006-01       Impact factor: 12.944

3.  Inhibitory effect of the oral immune response modifier, bestatin, on cell-mediated and cell-free HIV infection in vitro.

Authors:  A S Bourinbaiar; S Lee-Huang; K Krasinski; W Borkowsky
Journal:  Biomed Pharmacother       Date:  1994       Impact factor: 6.529

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.